Incannex Partners with the Monash Trauma Group to assess IHL-216A in a model of sports concussion

Clinical stage cannabinoid development company, Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’), is pleased to announce that it has partnered with the Monash Trauma Group at the Department of Neuroscience to conduct an extensive in vivo study in relation to the neuroprotective capability of IHL-216A; a proprietary combination pharmacotherapy (drug) comprising cannabidiol (‘CBD’) and isoflurane.